Best AudioMedica.com Podcasts (2025)

1
Single-cell RNA Sequencing Provides Comprehensive Map of Acute Myeloid Leukemia Cell States 15:01

11d ago15:01

15:01

An interview with: Andy Zeng, MD/PhD candidate, University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada With comment from: Hussein A Abbas MD PhD, Assistant Professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston TX CHICAGO—A research study using single-cell RNA sequencing data has created a new …

1
Yelena Y Janjigian MD: PD-1 Blockade Directed by ctDNA Delayed Recurrence in Mismatch Repair Deficient Solid Tumors After Surgery and Standard of Care 9:47

20d ago9:47

9:47

An interview with: Yelena Y Janjigian MD, Medical Oncologist, Chief of Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York. CHICAGO, USA—Patients with early-stage solid cancers with DNA mismatch repair-deficiency (also known as microsatellite instability) benefitted greatly if they received anti-programmed death-1 (P…

1
Paolo Marchetti MD: Tissue or Liquid Biopsy? Both Together Could Be Best for Advanced Solid Tumor Therapy Planning 9:54

24d ago9:54

9:54

The Audio Journal of Oncology talks with: Paolo Marchetti MD, Scientific Director, Istituto Dermatopatico dell’Immacolata, Rome And with: Elaine R. Mardis, PhD FAACR, Co-Executive Director of the Steve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children’s Hospital, Rasmussen Nationwide Foundation Endowed Chair in Genomic Medicin…

1
Patients with Relapsed or Refractory Acute Myeloid Leukemia have Remissions with “Logic Gated” Off-the-Shelf Natural Killer Cell Therapy 14:12

25d ago14:12

14:12

An Interview with: Stephen Strickland, Jr. MD MSCI, Director, Leukemia Research; Executive Chair, Leukemia Research Committee, Sarah Cannon Research Instiute, Nashville, Tennessee USA CHICAGO – Several patients with acute myeloid leukemia, who were treated with SENTI-202, a first-in-class chimeric antigen receptor (CAR) natural killer (NK) cell the…

1
More Breast Cancer Cases in Younger Women since 2010 But Fewer Deaths 14:50

26d ago14:50

14:50

An interview with: Adetunji T. Toriola, MD, PhD, MPH, Professor of Surgery, Department of Surgery and Division of Public Health Sciences, Washington University School of Medicine and Siteman Cancer Center, St Louis, Missouri, USA And with: Elaine R. Mardis, PhD FAACR, Co-executive director of the Steve and Cindy Rasmussen Institute for Genomic Medi…

1
Fast, Accurate Artificial Intelligence Method to Diagnose and Classify Pediatric Sarcoma Anywhere 15:56

27d ago15:56

15:56

An interview with: Adam Thiesen, PhD Candidate, UConn Health, University of Connecticut and the Jackson Laboratory for Genomic Medicine, Farmington, CT And with: Jayesh Desai MD, Medical Oncologist, Associate Director Clinical Research, Peter MacCallum Cancer Centre, Melbourne, Australia, Co-Chair, AACR Clinical Committee. CHICAGO – An artificial i…

1
EGFR-Sparing Anti-HER2 Drug Benefits Patients with Advanced HER2-Mutated Non-Small Cell Lung Cancer 12:59

28d ago12:59

12:59

An interview with: John V Heymach MD PhD, Professor and Chair of Thoracic/Head and Neck Medical Oncology, Ruth Legett Jones Distinguished Chair, University of Texas MD Anderson Cancer Center, Houston TX And with: Jayesh Desai MD, Medical Oncologist, Associate Director Clinical Research, Peter MacCallum Cancer Centre, Melbourne, Australia, Co-Chair,…

1
Neoadjuvant PD-1 Blockade Enables Patients with Mismatch Repair Deficient Colorectal Cancers to Avoid Surgery 14:03

30d ago14:03

14:03

An interview with: Andrea Cercek MD, Gastrointestinal Cancer Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York And: Ryan B Corcoran MD PhD, Director of the GI Cancer Program, Massachusetts General Hospital Cancer Center, Boston MA CHICAGO—The Audio Journal of Oncology reports on the neoadjuvant use of programmed cell-death protei…

1
Topical BRAF-inhibiting Gel Controls Acneiform Rash in Patients with Colorectal Cancer Treated with EGFR-inhibition 8:45

1M ago8:45

8:45

An interview with: Anisha B Patel MD, Associate Professor of Dermatology, Division of Internal Medicine, MD Anderson Cancer Center, Houston TX CHICAGO, USA—Acneiform rash toxicities caused by anti- epidermal growth factor receptor (EGFR) therapies were markedly reduced among patients with colorectal cancer in a double-blind placebo-controlled, rand…

1
Adding Perioperative Pembrolizumab to Standard of Care Improves Outcomes in Patients with Newly Diagnosed Head and Neck Cancers 13:26

1M ago13:26

13:26

Interviews with: Ravindra Uppaluri, MD PhD, Director of Head and Neck Surgical Oncology, Dana Farber Brigham Cancer Center, Boston MA; And: Ryan B Corcoran MD PhD, Director of the gastrointestinal cancer program, Massachusetts General Hospital Cancer Center, Associate Professor of Medicine Harvard Medical School and Co-Chair of the American Associa…

1
RAS Inhibitor Zoldonrasib Brings Clinical Benefit in Patients with G12D Mutated Non-Small Cell Advanced Lung Cancer 12:15

1M ago12:15

12:15

An interview with: Kathryn C Arbour MD, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center, New York USA And: Ryan B Corcoran MD PhD, Massachusetts General Cancer Center, Associate Professor of Medicine Harvard Medical School, Co-Chair, American Association for Cancer Research Clinical Trials Committee CHICAGO, USA— The four per ce…

1
Two Checkpoint Inhibitors in One Bispecific Molecule Improved Survival in Patients with High-Risk Gastric Cancer 10:10

1M ago10:10

10:10

An interview with: Jiafu Ji MD PhD DrPH FRCS, Fellow of the Chinese Academy of Medical Science, Professor and Chief, Gastrointestinal Cancer Center, Peking University Cancer Hospital, Beijing Institute for Cancer Research, Beijing, China Sarah Maxwell, Audio Journal of Oncology: The idea of harnessing two different pathways of checkpoint inhibition…

1
Exosome Liquid Biopsy for Earliest Pancreatic Cancer Detection 13:10

2M ago13:10

13:10

An interview with: Ajay Goel PhD, Chair of the Molecular Diagnostics and Experimental Therapeutics Department, Beckman Research Institute, City of Hope, Los Angeles California. SAN DIEGO—The prospect of detecting pancreatic cancer at very early stages, when cure may be possible, is now being held out by research showing that the sub-cellular molecu…

1
Long Remissions with Bispecific T-cell Engager Antibody Therapy for Patients with Relapsed Multiple Myeloma 15:43

2M ago15:43

15:43

An interview with: Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology, Director of the Center of Excellence for Multiple Myeloma, Icahn School of Medicine, Mount Sinai, New York. Sarah Maxwell, Audio Journal of Oncology: “An exciting, new immunotherapy treatment for multiple myeloma, was under discussion at the 2024 Ameri…

1
Personalized Vaccine Brought Durable Immune Responses and Fewer Relapses in Head and Neck Cancers 13:33

2M ago13:33

13:33

An interview with: Olivier Lantz MD PhD, Head of the Clinical Immunology Laboratory, Institut Curie, Paris, France PARIS, France—A clinical trial using a personalized therapeutic vaccine, that recognizes multiple genetic features of each patient’s tumor, brought durable tumor-specific immune responses in patients with surgically resected HPV-negati…

1
Adding Anthracycline Improved Outcomes for Patients with High-Risk HR-positive, HER2-negative Breast Cancer 7:56

2M ago7:56

7:56

SAN ANTONIO, USA—Women with hormone receptor positive HER-2 negative breast cancer and Oncotype DX recurrence scores above 31 could benefit from having anthracycline therapy added to their taxane-based chemotherapy, according to breast medical oncologist and assistant professor of internal medicine, Nan Chen MD, from the University of Chicago. She …

1
Specific Subgroups of Patients with Metastatic Castration Resistant Prostate Cancer Live Longer with Talazoparib Added to their Enzalutamide Therapy 22:08

3M ago22:08

22:08

SAN FRANCISCO, CA—Adding the poly ADP ribose polymerase (PARP) inhibitor drug talazoparib to standard anti-androgen therapy with enzalutamide statistically significantly extended overall survival among patients whose metastatic castration resistant prostate cancers had specific molecular markers. This finding was reported at the 2025 American Socie…

1
Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab 13:37

3M ago13:37

13:37

Audio Journal of Oncology Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab LOS ANGELES, CA—Single agent immunotherapy with the anti-programmed death-1 (PD-1) agent pembrolizumab resulted in markedly high melanoma-specific survival rates among patients with either resectable or metastatic desmoplastic mel…

1
Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer 13:20

3M ago13:20

13:20

Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer The important question of whether to recommend risk-reducing surgery to patients who are carriers of pathogenic mutations in either BRCA1 or BRCA2 genes (or both), and have already developed breast cancer, has been i…

1
E. Shelley Hwang MD MPH: Randomized Study Found Surgery-Sparing Active Monitoring Safe in Patients With Low-risk DCIS 13:47

5M ago13:47

13:47

SAN ANTONIO, USA—In patients with hormone receptor-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS) active monitoring, compared with surgery, resulted in no difference in terms of cancer outcomes in the multicenter, randomized COMET study that compared oncologic outcomes of patients randomized to guideline-concordant care (with sur…

1
AUDIO JOURNAL OF ONCOLOGY: Safe to Spare Post-Mastectomy Chest Wall Radiotherapy in Most Patients with Intermediate Risk Breast Cancer 15:27

5M ago15:27

15:27

SAN ANTONIO, USA—There was no benefit from chest wall irradiation in patients who had intermediate-risk breast cancer, according to findings reported at the 2024 San Antonio Breast Cancer Symposium from the BIG 2-04 MRC SUPREMO international phase three randomized controlled trial. At the conference Ian Kunkler MA, MB, BChir, Professor at Edinburgh…

1
Jenny Paredes PhD, Duarte, CA: Increased Dietary Fiber Brings Longer Survival and Less GVHD After Allogeneic Stem Cell Transplantation 12:28

5M ago12:28

12:28

An interview with: Jenny Paredes PhD, of the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope National Medical Center in Duarte, California SAN DIEGO, USA—A higher intake of dietary fiber after allogeneic hematopoietic cell transplantation was associated with increased overall survival, a lower incidence of graft-vers…

1
Adding a Bi-Specific T-Cell Engager Brings Striking Benefit in Childhood Acute Lymphoblastic Leukemia 13:07

6M ago13:07

13:07

SAN DIEGO, USA—When added to standard chemotherapy the bi-specific T-cell engager drug blinatumomab brought a large, statistically significant improvement in disease-free survival in a randomized controlled study of 1731 children with average or higher relapse-risk B-cell acute lymphoblastic leukemia. Study first author Rachel E. Rau MD, from the S…

1
Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia 7:26

6M ago7:26

7:26

Audio Journal of Oncology PodcastDecember, 2024: Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia Hua Zhang MD PhD (Chief Scientific Officer with SPH Biotherapeutics Limited, Shanghai and Hong Kong, China) tells the Audio Journal about the research findings he reported to the 2024 Annual Meeting o…

1
Low Rates of Early Detection Drive Excess Breast Cancer Mortality in Underserved Communities 24:31

2y ago24:31

24:31

BRIGHTON, UK—In underserved communities throughout the world low rates of early breast cancer detection are key drivers of mortality, according to the findings of research from Uganda, the United Kingdom and Nigeria. A range of low cost community-based interventions could be used to modify these drivers, the research concludes. Huge reductions of b…

1
AUDIO JOURNAL OF ONCOLOGY—Options Identified for Chemotherapy Intensity Reduction in Acute Lymphoblastic Leukemia 13:34

2+ y ago13:34

13:34

Audio Journal of Oncology, February 14 2023, Reporting from the American Society of Hematology Annual Meeting (ASH), December 2022 An interview with Amy A. Kirkwood MSc, Senior Statistician at the Cancer Research UK & UCL Cancer Trials Centre, University College, London, UK Interviewer: Peter M Goodwin TITLE: Options Identified for in Acute Lymphob…

1
AUDIO JOURNAL OF ONCOLOGY—Don’t Delay Stem Cell Transplant For Patients with Relapsed or Refractory Acute Myeloid Leukemia 15:06

2+ y ago15:06

15:06

Interview with Matthias Stelljes MD, Head of the Allogeneic Stem Cell Program at the University of MÃ¼nster, Germany NEW ORLEANS, USA—For your patients with acute myeloid leukemia (AML) the benefit of prompt allogeneic hematopoietic cell transplantation (alloHCT) extends to those whose disease has relapsed or is refractory to induction therapy, and…

1
AUDIO JOURNAL OF ONCOLOGY—Ibrutinib Enables Transplant-Free Therapy for Mantle Cell Lymphoma 16:28

2+ y ago16:28

16:28

Ibrutinib Enables Transplant-Free Therapy for Mantle Cell Lymphoma NEW ORLEANS, USA—Many patients eligible for autologous stem cell transplantation for their mantle cell lymphoma (under current best practice recommendations) could be treated as effectively—and potentially with less toxicity—with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutini…

1
AUDIO JOURNAL OF ONCOLOGY—Fast Durable Responses to Bi-Specific Antibody Therapy In Heavily Pre-Treated Multiple Myeloma 20:54

2+ y ago20:54

20:54

January 10, 2023 Fast Durable Responses to Bi-Specific Antibody Therapy In Heavily Pre-Treated Multiple Myeloma INTERVIEW WITH: Ajai Chari MD, Associate Professor of Medicine and Director of Clinical Research in the Multiple Myeloma Program at Mount Sinai School of Medicine in New York, USA. NEW ORLEANS, USA—The bispecific antibody talquetamab, cla…

1
AUDIO JOURNAL OF ONCOLOGY—High Response Rates in Lung Cancer from Next Generation ROS1 Inhibitor 12:07

2+ y ago12:07

12:07

An interview with: Byoung Chul Cho MD PhD, Thoracic Medical Oncologist, from the Yonsei Cancer Center at Yonsei University College of Medicine in Seoul, South Korea. BARCELONA, Spain—A “next generation” ROS1 tyrosine kinase inhibitor (TKI), repotrectinib—studied in the phase one/two Trident-1 study among patients whose advanced non-small cell lung …

1
AUDIO JOURNAL OF ONCOLOGY – ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy 13:59

2+ y ago13:59

13:59

ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy BARCELONA, Spain—Findings from a study of a new investigational therapy targeting the ROS-1 receptor tyrosine kinase—mutated in some cancers—were reported at the 2022 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics conference held in Barcelona. First…

1
AUDIO JOURNAL OF ONCOLOGY—Pan-AKT Inhibitor Tumor Agnostic Targeting was Safe and Effective in Phase One Study 10:16

2+ y ago10:16

10:16

Pan-AKT Inhibitor Tumor Agnostic Targeting was Safe and Effective in Phase One Study BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT inhibitor ipatasertib in a phase one study reported at the 2022 EORTC—NCI—AACR symposium on Molecular Targets and Cancer Therapeutics. Nearly a quarter …

1
AUDIO JOURNAL OF ONCOLOGY—MYC-Targeted Drug Had Excellent Safety And Solid Tumor Responses 9:13

2+ y ago9:13

9:13

BARCELONA, Spain—Although having a mutated MYC molecule is a distinguishing molecular factor in many solid tumors it has been considered “undruggable” — having a shortage of potential and actual mechanisms for cancer inhibition. But it now looks as though MYC could be a viable target for cancer drugs. A phase one study of a “pan-MYC inhibitor” OMO …

1
AUDIO JOURNAL OF ONCOLOGY—New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma 17:40

2+ y ago17:40

17:40

New Molecular Drug has Clinical Activity in Hepatocellular Carcinoma Interview with: Maria Reig MD PhD, Professor and Head of the Barcelona Clinic Liver Cancer (BCLC) Unit, Hospital Clinic Barcelona at Barcelona University, Spain. BARCELONA, Spain—A phase one study of new drug targeting the monopolar spindle 1 enzyme was found to be safe—with rever…

1
AUDIO JOURNAL OF ONCOLOGY—Cell Therapy Markedly Improved Outcomes After Immunotherapy in Melanoma 5:59

2+ y ago5:59

5:59

PARIS, France—Patients who had cell therapy as second-line treatment for their advanced melanoma lived twice as long without disease progression compared with those who merely continued with pure immunotherapy. This finding came from a phase three randomized study reported at the 2022 Congress of the European Society for Medical Oncology (ESMO) by …

1
AUDIO JOURNAL OF ONCOLOGY—Glioma in Adults: Next Generation Sequencing Validates BRAF Targeting 8:33

2+ y ago8:33

8:33

BARCELONA, Spain—Next generation sequencing is now an essential part of care for glioma in adults, according to research on BRAF targeting as treatment for this disease reported at the 2022 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. Karisa Schreck MD PhD, from Johns Hopkins Hospital, Baltimore, Maryland in the USA talked wi…

1
AUDIO JOURNAL OF ONCOLOGY—First Line Atezolizumab Extends Life in Unfit Patients with Lung Cancer 7:01

2+ y ago7:01

7:01

PARIS, France—the open-label international phase three randomized IPSOS study reported at the 2022 European Society for Medical Oncology congress that patients with non-small cell lung cancer who were not fit enough to be recommended standard platinum doublet chemotherapy lived longer when treated with the programmed death-ligand 1 (PD-L1) inhibito…

1
AUDIO JOURNAL OF ONCOLOGY—Breast Conservation: Machine-Learning Helps De-Escalate Breast Cancer Therapy 8:14

2+ y ago8:14

8:14

HEIDELBERG, Germany—AndrÃ© Pfob, Clinical Research Assistant from the University Breast Unit at Heidelberg University Hospital, Germany tells the Audio Journal of Oncology’s correspondent Peter Goodwin about the machine learning techniques his group has been using to help identify patients who can be spared further treatment after neo-adjuvant ther…

1
AUDIO JOURNAL OF ONCOLOGY—PARP-Inhibition Beyond Initial Therapy Extends Life with Advanced Ovarian Cancer 6:09

2+ y ago6:09

6:09

PARIS, France—Long remissions and potential cures� were reported at the 2022 Annual Meeting of the European Society for Medical Oncology (ESMO) in patients with newly diagnosed advanced ovarian cancers expressing the BRCA mutation who were treated with the poly ADP ribose polymerase (PARP) inhibitor olaparib after initial therapy. Two thirds of wom…

1
Progression to Acute Myeloid Leukemia Explained by Multi Omics Analysis 20:54

2+ y ago20:54

20:54

ATLANTA, USA—A new research method has elucidated cellular processes (involving mutated TP53 oncogene) that can convert a relatively benign myeloproliferative neoplasm into acute myeloid leukemia. Findings from Oxford University in the UK (using the novel genetic sequencing tool called: single cell multi omics) were reported at the American Society…

1
AUDIO JOURNAL OF ONCOLOGY—“PM 2.5” Evidence Links Particulate Air Pollution to Non-Small Cell Lung Cancer 7:14

2+ y ago7:14

7:14

PARIS, France—Particulate air pollution was identified as a key step in malignant transformation from benign DNA to non-small cell lung cancer according to a report delivered to the 2022 Congress of the European Society for Medical Oncology (ESMO). Charles Swanton FRCP BSc PhD, Professor and Senior Group Leader of the Francis Crick Institute, Consu…

1
CT Screening Cuts Lung Cancer Deaths 24-Per Cent Second Study Confirms

5+ y ago

—

UK & NETHERLANDS—Following the the AJO Podcast interview with Professor Harry de Koning MD PhD, from the Erasmus University in Rotterdam, who discussed his research published in the New England Journal of Medicine that supports the widespread introduction of computed tomographic (CT) screening to detect lung cancer, this edition of the podcast hear…

1
Volume CT Lung Cancer Screening Cuts Cancer Deaths 24 Per Cent 16:39

5+ y ago16:39

16:39

Second Study Confirms Lung Cancer CT Screening Cuts Deaths NETHERLANDS—Erasmus University Medical Center, Rotterdam—Research published in the New England Journal of Medicine has confirmed the viability of computed tomographic (CT) screening for detecting cases of lung cancer early in high-risk individuals—namely those who smoke heavily and or have …

1
New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia 3:00

5+ y ago3:00

3:00

Audio Journal of Oncology SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclusions drawn from the Alliance North American Intergroup Study A041202 reported at the 2018 Annual Meeting of the American Society of Hematology (ASH). “Unless there…

1
Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation 10:00

5+ y ago10:00

10:00

Microbiome Diversity Key To Survival After Allogeneic Hematopoietic Cell Transplantation The Audio Journal of Oncology Podcast SAN DIEGO—Overall survival after allogeneic hematopoietic cell transplantation (allo-HCT) was found to be adversely influenced by a lack of diversity in the intestinal microbiota—before, during and after the transplant—in a…

1
Genomic-led AML Clinical Decision Making Within Seven Days 11:00

5+ y ago11:00

11:00

Audio Journal of Oncology Reporting from 2018 annual meeting of the American Society of Hematology INTERVIEW WITH: John C. Byrd MD, Chief Medical Officer for the “Beat AML Trial” , Chair of Leukemia Research, Senior Advisor for Cancer Experimental Therapeutics at Ohio State University Comprehensive Cancer Center, Columbus OH. SAN DIEGO, USA—Individ…

1
Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia? 10:00

5+ y ago10:00

10:00

SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irreversible inhibitor of Bruton’s tyrosine kinase [BTK]) combined with the anti-CD 20 agent rituximab than patients in a control arm receiving standard fl…

1
Head and Neck Cancer Therapy De-Escalation: A “Salutary Lesson”

6+ y ago

—

MUNICH—A “salutary lesson” was reported by researchers investigating therapy for oropharyngeal cancer at the 2018 annual congress of the European Society for Medical Oncology (ESMO). It came from results of the De-ESCALaTE HPVstudy that found patients with low-risk head and neck cancer who tested positive for human papilloma virus (HPV+) did better…

Podcasts Worth a Listen

AudioMedica.com Podcasts

Podcasts Worth a Listen

Quick Reference Guide